|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of goods sold(1) | |||||
| Gross profit | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Operating income | |||||
| Loss on early extinguishment of debt | |||||
| Net interest expense | |||||
| Gain on sale of investment | |||||
| Other expense (income) | |||||
| Income before income taxes | |||||
| Provision (benefit) for income taxes | |||||
| Net income from continuing operations | |||||
| Income from discontinued operations, net of tax | |||||
| Net income | |||||
| Changes in cumulative translation adjustment (2025 includes $92.7 million reclassified to gain on sale included in Income from discontinued operations, net of tax) | |||||
| Changes in market value of derivative financial instruments, net of tax | |||||
| Comprehensive income attributable to nVent | |||||
| Earnings per ordinary share | |||||
| Basic | |||||
| Discontinued operations (in dollars per share) | |||||
| Continuing operations (in dollars per share) | |||||
| Basic (dollars per share) | |||||
| Diluted | |||||
| Continuing operations (in dollars per share) | |||||
| Discontinued operations (in dollars per share) | |||||
| Diluted (dollars per share) | |||||
| Weighted-average ordinary shares outstanding | |||||
| Basic (shares) | |||||
| Diluted (shares) | |||||
Loading...
